Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
586 Leser
Artikel bewerten:
(2)

Natus Medical Incorporated Announces Closing of Acquisition of Micromed Holding SAS

Newly merged organization brings together innovative neurodiagnostic and neuromonitoring solutions and experienced teams to offer a broader portfolio of products, services and support to customers worldwide.

MIDDLETON, Wis., Jan. 18, 2023 /PRNewswire/ -- Natus Medical Incorporated (the "Company" or "Natus"), a leading provider of medical device solutions focused on the screening, diagnosis and treatment of central nervous and sensory system disorders, today announced the closing of its acquisition of Micromed Holding SAS ("Micromed"), a global provider of neurophysiology solutions. Micromed products will be added to the Natus Neuro portfolio and developed alongside Natus technologies.

"We are thrilled to complete this deal and move forward combining the Natus and Micromed teams and product portfolios," said Austin Noll, Natus President and leader of Natus Neuro. "Together we will be able to provide our neuroscience customers a more comprehensive product offering and unrivaled global service and support through the increased breadth and depth of our combined resources."

The Natus legacy of over 85 years of neurodiagnostic leadership will grow through the addition of the complete line of Micromed solutions to comprise an even stronger portfolio of products across electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU) monitoring. Together the products and organizational experience will bring incremental value to customers around the world, while also providing a strong platform for new product development.

"The Micromed team is excited to bring our passion, our experience, our products and our European leadership to Natus," said Cristiano Rizzo, General Manager of Micromed. "As we expand through the extensive Natus structure, we will continue to cultivate the customer and key opinion leader relationships that we have established at Micromed over the years."

This acquisition is the first by Natus since its de-listing from the NASDAQ in July, 2022 and reflects a commitment to invest in growth. "The acquisition of Micromed is the first transaction in our acquisition roadmap to build leading companies in both Neuro and Sensory under the Natus umbrella," said Thomas J. Sullivan, Natus Chief Executive Officer. "This is a significant milestone for Natus, our customers and their patients."

About Natus - www.natus.com -Natus delivers innovative and trusted solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. The Company offers hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture the body's response. With sales in over 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging, and infant hearing screening, as well as a leading company in hearing assessment, hearing instrument fitting, balance, and intracranial pressure monitoring. The Natus product portfolio represents a heritage of innovation and leadership. Natus brands have been setting the standard for patient care for over 85 years. Our products are trusted by medical professionals in university medical centers, hospitals, private practices, clinics and research laboratories around the world. Natus supports our customers' evolving needs with clinical expertise, continuing education, and outstanding technical service.

About Micromed - Founded in 1982, Micromed is a medical device company delivering solutions in Neurophysiology to over 78 countries worldwide. Partnering with hospitals, sleep labs and research centers on a global scale, Micromed manufactures and markets high quality, cost effective and clinically relevant neurodiagnostic hardware and software to neurologists, clinicians and researchers for use on adult and pediatric patients. The Micromed product portfolio ranges from Routine, Ambulatory and Video EEG to electrocorticography (ECoG), stereoelectroencephalography (SEEG), PSG, evoked potentials (EP), EMG and ICU multimodal monitoring solutions for clinical and research.

Contacts:

Natus Medical Incorporated
InvestorRelations@Natus.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/natus-medical-incorporated-announces-closing-of-acquisition-of-micromed-holding-sas-301723746.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.